Cholinesterases: new roles in brain function and in Alzheimer's disease (Q35098528)

6 August 2017

1 reference

title

Cholinesterases: new roles in brain function and in Alzheimer's disease (English)

1 reference

6 August 2017

0 references

Ezio Giacobini

1

1 reference

6 August 2017

publication date

1 April 2003

1 reference

6 August 2017

published in

Neurochemical Research

1 reference

6 August 2017

volume

28

1 reference

6 August 2017

issue

3-4

1 reference

6 August 2017

page(s)

515-522

1 reference

https://scigraph.springernature.com/pub.10.1023/a:1022869222652

6 August 2017

exact match

0 references

cites work

Acetylcholinesterase promotes the aggregation of amyloid-beta-peptide fragments by forming a complex with the growing fibrils.

1 reference

12 December 2020

Neurological cholinesterases in the normal brain and in Alzheimer's disease: relationship to plaques, tangles, and patterns of selective vulnerability.

1 reference

12 December 2020

A structural motif of acetylcholinesterase that promotes amyloid beta-peptide fibril formation

1 reference

12 December 2020

Molecular isoform distribution and glycosylation of acetylcholinesterase are altered in brain and cerebrospinal fluid of patients with Alzheimer's disease.

1 reference

12 December 2020

Phenserine regulates translation of beta -amyloid precursor protein mRNA by a putative interleukin-1 responsive element, a target for drug development

1 reference

12 December 2020

Coadministration of cholinesterase inhibitors and idazoxan: effects of neurotransmitters in rat cortex in vivo

1 reference

12 December 2020

Selective inhibitors of butyrylcholinesterase: a valid alternative for therapy of Alzheimer's disease?

1 reference

12 December 2020

Acetylcholinesterase accelerates assembly of amyloid-beta-peptides into Alzheimer's fibrils: possible role of the peripheral site of the enzyme.

1 reference

12 December 2020

Cholinesterase inhibitors, beta-amyloid precursor protein and amyloid beta-peptides in Alzheimer's disease.

1 reference

12 December 2020

Release of Alzheimer amyloid precursor derivatives stimulated by activation of muscarinic acetylcholine receptors

1 reference

12 December 2020

Butyrylcholinesterase and cognitive function.

1 reference

12 December 2020

Changes in brain cholinesterases in senile dementia of Alzheimer type

1 reference

12 December 2020

Butyrylcholinesterase reactivity differentiates the amyloid plaques of aging from those of dementia.

1 reference

12 December 2020

Cholinesterase inhibitors increase secretion of APPs in rat brain cortex

1 reference

12 December 2020

Molecular physiology, biochemistry, and pharmacology of Alzheimer's amyloid precursor protein (APP).

1 reference

12 December 2020

Special properties of cholinesterases in the cerebral cortex of Alzheimer's disease.

1 reference

12 December 2020

Cholinesterase inhibitor effects on neurotransmitters in rat cortex in vivo.

1 reference

12 December 2020

Acetylcholinesterase is increased in the brains of transgenic mice expressing the C-terminal fragment (CT100) of the beta-amyloid protein precursor of Alzheimer's disease.

1 reference

12 December 2020

Acetylcholinesterase-amyloid-beta-peptide interaction and Wnt signaling involvement in Abeta neurotoxicity.

1 reference

12 December 2020

Acetylcholinesterase knockouts establish central cholinergic pathways and can use butyrylcholinesterase to hydrolyze acetylcholine

1 reference

12 December 2020

Inhibition of acetyl- and butyryl-cholinesterase in the cerebrospinal fluid of patients with Alzheimer's disease by rivastigmine: correlation with cognitive benefit

1 reference

12 December 2020

Reversible and irreversible acetylcholinesterase inhibitors cause changes in neuronal amyloid precursor protein processing and protein kinase C level in vitro.

1 reference

12 December 2020

Increased biosynthesis of Alzheimer amyloid precursor protein in the cerebral cortex of rats with lesions of the nucleus basalis of Meynert

1 reference

12 December 2020

Galantamine in AD: A 6-month randomized, placebo-controlled trial with a 6-month extension. The Galantamine USA-1 Study Group.

1 reference

12 December 2020

Identifiers

DOI

10.1023/A:1022869222652

1 reference

Dimensions Publication ID

6 August 2017

1025157245

0 references

1 reference